I

Imexpharm Corp
VN:IMP

Watchlist Manager
Imexpharm Corp
VN:IMP
Watchlist
Price: 52 500 VND Market Closed
Market Cap: 8.1T VND

Relative Value

The Relative Value of one IMP stock under the Base Case scenario is 51 764.37 VND. Compared to the current market price of 52 500 VND, Imexpharm Corp is Overvalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMP Relative Value
Base Case
51 764.37 VND
Overvaluation 1%
Relative Value
Price
I
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
11
vs Industry
36
Median 3Y
2.5
Median 5Y
1.4
Industry
2.6
Forward
3.1
vs History
14
vs Industry
20
Median 3Y
21.1
Median 5Y
11
Industry
21.4
Forward
23.3
vs History
vs Industry
14
Median 3Y
5.7
Median 5Y
7.8
Industry
16.4
vs History
3
vs Industry
12
Median 3Y
19.3
Median 5Y
13.7
Industry
22.8
vs History
7
vs Industry
23
Median 3Y
2.5
Median 5Y
1.1
Industry
2.2
vs History
9
vs Industry
37
Median 3Y
2.4
Median 5Y
1.4
Industry
2.9
Forward
3.1
vs History
14
vs Industry
27
Median 3Y
6.5
Median 5Y
3.5
Industry
5.5
vs History
12
vs Industry
27
Median 3Y
11.5
Median 5Y
6.2
Industry
13
Forward
13.5
vs History
17
vs Industry
25
Median 3Y
15.1
Median 5Y
7.8
Industry
16.5
Forward
17.1
vs History
vs Industry
14
Median 3Y
4.7
Median 5Y
7.7
Industry
15.6
vs History
vs Industry
8
Median 3Y
4.9
Median 5Y
7.3
Industry
18.7
vs History
12
vs Industry
24
Median 3Y
2.3
Median 5Y
1
Industry
1.9

Multiples Across Competitors

IMP Competitors Multiples
Imexpharm Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Imexpharm Corp
VN:IMP
8.1T VND 3.3 25.3 14.4 17.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.9 38.1 40.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.3B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
269.9B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
220.1B GBP 5.1 31.5 108.7 159.1
US
Merck & Co Inc
NYSE:MRK
270.1B USD 4.2 14.2 10.1 11.9
CH
Novartis AG
SIX:NOVN
218.2B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
VN
I
Imexpharm Corp
VN:IMP
Average P/E: 25.1
25.3
15%
1.7
US
Eli Lilly and Co
NYSE:LLY
56.9
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.5
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBITDA: 401.4
14.4
15%
1
US
Eli Lilly and Co
NYSE:LLY
38.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBIT: 1 714.1
17.7
18%
1
US
Eli Lilly and Co
NYSE:LLY
40.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5